Genenforce and Hibiscus BioVentures Announce Strategic Partnership to Enable Advanced Therapeutics Development

Jianxin Force, a company focusing on the development and biomanufacturing of advanced therapy drugs (“Advanced Therapy Medicinal Products ATMPs”), and Hibiscus BioVentures in the United States, are committed to building different companies focusing on patients around transformative technologies, and recently announced the establishment of a strategic partnership relationship
.
Both parties will pool their respective rich resources to advance new ATMPs and biopharmaceuticals to accelerate the development of Hibiscus BioTechnology Studio Companies' pipeline of products
.
Chris Jeffers, Chief Executive Officer of Hibiscus BioTechnology, said, "This strategic partnership with Jianxin Forces underscores our commitment to growing Hibiscus Studio's pipeline, enhancing our operational capabilities, and advancing the development and commercialization of innovative medicines.

"We are delighted to partner with Hibiscus, who have brought an experienced and senior team with a unique model to develop emerging technologies to continuously address the medical needs of patients
.
" said Dr.
Yuling Li, co-founder and CEO of Jianxin Forces , "This collaboration strongly combines our drug development experience with the Hibiscus product pipeline, enabling the advancement of emerging and advanced biotherapeutics development globally
.
" About Hibiscus BioVentures Hibiscus BioVentures is committed to supporting commercialization by supporting The development of therapeutics, advancing services to patients, and building patient-centric companies around a variety of transformative technologies
.
Hibiscus has two operating subsidiaries, Hibiscus BioTechnology and Hibiscus Capital Management
.
About Jianxin Yuanli Jianxin Yuanli is a biopharmaceutical company focused on innovation and partnership to promote and accelerate the innovation of breakthrough advanced therapeutic medicines (ATMPs)
.
The company's biopharmaceutical manufacturing and development capabilities will serve global markets using its facility in Hangzhou, China, and an office in Rockville, Maryland, USA
.
Jianxin Force provides end-to-end contract development and manufacturing services (CDMO), including GMP commercial production of plasmid DNA, RNA, viral vectors and cell therapy products
.
In addition, Jianxin Forces provides antibody and protein drug CDMO services through a joint venture with a leading international provider of life science products and services
.
The company also has capabilities in incubating and developing advanced biological therapies such as cell therapy and gene therapy, enabling partners and portfolio companies to more efficiently deliver cutting-edge therapies that impact the lives of patients around the world
.